Results 21 to 30 of about 537,505 (139)

Inhibition of Protein Synthesis by Didemnin B:  How EF-1α Mediates Inhibition of Translocation†

open access: yes, 2016
The antineoplastic cyclic depsipeptide didemnin B (DB) inhibits protein synthesis in cells and in vitro. The stage at which DB inhibits protein synthesis in cells is not known, although dehydrodidemnin B arrests translation at the stage of polypeptide ...
Bhagyashri V. SirDeshpande (2951778)   +6 more
core   +1 more source

Clonación y expresión recombinante del factor de elongación-1α de Leishmania infantum

open access: yes, 2023
Introduction. In visceral leishmaniasis (VL), in old world caused by Leishmania donovani, elongation factor-1α (EF-1α) is an antigen-activator of SHP-1 phosphatase that inhibits the leishmanicidal activity of macrophages.
Castro García, Israel   +5 more
core  

Innovation of plant‐derived extracellular vesicles and interdisciplinary research: From discovery to biomedical applications

open access: yesBMEMat, EarlyView.
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li   +6 more
wiley   +1 more source

PGC-1α and Myokines in the aging muscle : a mini-review [PDF]

open access: yes, 2011
Aging is associated with far-reaching changes in physiological functions resulting in morbidity and ultimately death. Age-related frailty, insecurity and reduced physical activity contribute to a progressive loss of muscle mass and function, commonly ...
Egger, A.   +5 more
core   +1 more source

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

The efficiency of CMV or EF-1α promoter in hADMPCs.

open access: yes, 2013
Lentiviral vectors encoding EGFP under the control of CMV or EF-1α promoter were transduced with hADMPCs at m.o.i. of 25, 50, 100, 250, 500, and 1000, and the cells were analyzed by flow cytometry.
Mariko Moriyama (420974)   +6 more
core   +1 more source

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang   +16 more
wiley   +1 more source

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer

open access: yesAdvanced Science, Volume 13, Issue 52, 18 September 2026.
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu   +13 more
wiley   +1 more source

The human elongation factor 1 alpha (EF-1α) first intron highly enhances expression of foreign genes from the murine cytomegalovirus promoter

open access: yes, 2002
In order to develop a highly efficient mammalian expression vector, we constructed a vector by the combination of the murine cytomegalovirus (MCMV) immediate early (IE) promoter and the human elongation factor one alpha (EF-1α) first intron.
Yeon Soo Kim   +4 more
core   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

open access: yesBiotechnology Progress, Volume 42, Issue 5, September/October 2026.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Home - About - Disclaimer - Privacy